Back to All Combinations

BRAF V600E (MSS)

Poor Prognosis
8.00% Prevalence Level 1 BRAF Pathway
Actionable Target
FDA-approved targeted therapies or strong clinical trial evidence available
Genes Involved
BRAF
Treatment Implications

FIRST-LINE (NEW 2025): Encorafenib + Cetuximab + mFOLFOX6 (BREAKWATER, OS 30.3 mo vs 15.1 mo - DOUBLES SURVIVAL). SECOND-LINE+: Encorafenib + Cetuximab doublet (BEACON, OS 9.3 mo).

Recommended Treatments
Encorafenib + Cetuximab + mFOLFOX6 (first-line)
Encorafenib + Cetuximab (second-line)
FOLFOXIRI + Bevacizumab
Treatments to Avoid
Anti-EGFR monotherapy
Study References

BREAKWATER (NEJM 2025), BEACON (PMID: 31566309)

Key Statistics
8.00%
Prevalence in CRC
Yes
Targetable
Clinical Notes
BREAKWATER 2025: Practice-changing for first-line BRAF V600E mCRC. PFS 12.8 vs 7.1 mo, OS 30.3 vs 15.1 mo. FDA accelerated approval. Always test for MSI-H as BRAF V600E + MSI-H has better prognosis.
Information

Category: BRAF Pathway

Evidence Level: Level 1

Last Updated: Dec 21, 2025

Related Combinations
Medical Disclaimer: This information is for educational purposes only and should not replace professional medical advice. Always consult with your oncologist for personalized treatment decisions based on your specific situation.